Statistical support for CLL and Richter's syndrome projects
Biostatistics
Using patient data and lab findings to find patterns that link molecular changes to outcomes in people with chronic lymphocytic leukemia (CLL) and Richter's syndrome.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179184 on NIH RePORTER |
What this research studies
This Biostatistics Core collects and curates clinical data from Dana‑Farber and collaborating sites and runs the analyses that link molecular and proteomic findings to patient outcomes. The team will look for Richter's‑specific changes in blood (cfDNA) and help interpret single‑cell and longitudinal tumor data. They also design and analyze animal experiments so results are statistically robust and reproducible. The Core keeps some lab teams blinded to outcomes so tests of predictive markers are not biased.
Who could benefit from this research
Good fit: People with chronic lymphocytic leukemia (CLL), especially those suspected of or at risk for Richter's transformation, and patients willing to share clinical data or provide blood samples for cfDNA testing.
Not a fit: People without CLL or Richter's syndrome, or patients seeking immediate changes to their individual treatment, are unlikely to receive direct benefit from this statistical core.
Why it matters
Potential benefit: If successful, the work could reveal blood markers and molecular signatures that predict Richter's transformation or treatment response, helping doctors act earlier and choose better therapies.
How similar studies have performed: Related studies using molecular profiling, cfDNA, and single‑cell analysis have found useful biomarkers in blood cancers, though reliably predicting Richter's transformation remains difficult.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Simon, Jeremy M. — Dana-Farber Cancer Inst
- Study coordinator: Simon, Jeremy M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.